Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077907 | 0.94 | HPGD (0.44) | USP2SMN1; SMN2CTSKHPGDMEN1 | |
| SCHEMBL13993957 | 0.90 | USP2 (0.42) | USP2SMN1; SMN2CTSKHPGDMEN1 | |
| SCHEMBL2887782 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2CTSKHPGDMEN1 | |
| SCHEMBL1118226 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2CTSKHPGDMEN1 | |
| SCHEMBL2110226 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2HPGDMEN1ALDH1A1 | |
| SCHEMBL18535153 | 0.83 | USP2 (0.43) | USP2SMN1; SMN2CTSKHPGDMEN1 | |
| SCHEMBL7014148 | 0.83 | USP2 (0.45) | USP2SMN1; SMN2CTSKHPGDMEN1 | |
| SCHEMBL849908 | 0.82 | USP2 (0.47) | USP2SMN1; SMN2CTSKHPGDMEN1 | |
| SCHEMBL16095422 | 0.82 | USP2 (0.47) | USP2SMN1; SMN2CTSKHPGDMEN1 | |
| SCHEMBL2892960 | 0.82 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180226-B2 | Spirotricycle RIPK1 inhibitors and methods of uses thereof | MERCK SHARP & DOHME LLC (US) | 2024-12-31 | — | — | US | disclosed |
| EP-4423096-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | Merck Sharp & Dohme LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118488957-A | Spirotricyclic RIPK1 inhibitors and methods of use thereof | 默沙东有限责任公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20230159558-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159558-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159558-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023076218-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076218-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2758389-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013040863-A1 | CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013041042-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013041042-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013043964-A1 | ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013043962-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| EP-1856110-B1 | OXYINDOLE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100173925-A1 | OXYINDOLE DERIVATIVES | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| US-7589109-B2 | Oxyindole derivatives | PFIZER INC (US) | 2009-09-15 | — | — | US | disclosed |
| US-20060194842-A1 | Oxyindole derivatives | PFIZER INC. | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173925-A1 | OXYINDOLE DERIVATIVES | HTR4, HTR5A, HRH4 | USP2 4396/4885SMN1; SMN2 326/4885CTSK 2606/4885 |
| US-20060194842-A1 | Oxyindole derivatives | HTR4, HTR5A, HRH4 | USP2 4396/4885SMN1; SMN2 326/4885CTSK 2606/4885 |
| US-12180226-B2 | Spirotricycle RIPK1 inhibitors and methods of uses thereof | RIPK1, RIPK3, RIPK4 | USP2 3467/4885SMN1; SMN2 4062/4885CTSK 548/4885 |
| US-20230159558-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | RIPK1, RIPK3, RIPK4 | USP2 3467/4885SMN1; SMN2 4062/4885CTSK 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.